What is Leerink Partnrs' Forecast for IDYA Q1 Earnings?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.66) for the quarter. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($2.45) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences' Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.75) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($2.81) EPS and FY2027 earnings at ($2.70) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.86).

Several other analysts have also recently commented on IDYA. UBS Group initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a "buy" rating and a $50.00 price target on the stock. Leerink Partners cut shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Oppenheimer reiterated an "outperform" rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Wedbush restated an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $53.67.

IDEAYA Biosciences Stock Down 5.4 %

IDYA stock traded down $1.19 during mid-day trading on Monday, hitting $20.76. The company had a trading volume of 1,245,177 shares, compared to its average volume of 862,268. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -8.91 and a beta of 0.82. IDEAYA Biosciences has a 12-month low of $20.66 and a 12-month high of $47.74. The company has a 50-day moving average price of $24.60 and a 200 day moving average price of $30.18.

Institutional Investors Weigh In On IDEAYA Biosciences

Large investors have recently added to or reduced their stakes in the stock. Covestor Ltd lifted its position in shares of IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock worth $29,000 after purchasing an additional 922 shares during the period. Allworth Financial LP lifted its position in IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company's stock valued at $29,000 after acquiring an additional 800 shares during the last quarter. R Squared Ltd purchased a new stake in IDEAYA Biosciences during the fourth quarter valued at approximately $35,000. US Bancorp DE lifted its position in IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after acquiring an additional 689 shares during the last quarter. Finally, KBC Group NV lifted its position in IDEAYA Biosciences by 29.1% during the third quarter. KBC Group NV now owns 2,274 shares of the company's stock valued at $72,000 after acquiring an additional 513 shares during the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.